TABLE 1.
Demographic and baseline characteristics at inclusiona
| Characteristic | Value(s) for subjects receiving: |
|||
|---|---|---|---|---|
| All subjects | 600 mg rifampin | 900 mg rifampin | 1,200 mg rifampin | |
| Total no. of subjects randomized | 150 | 50 | 50 | 50 |
| No. (%) of subjects by gender | ||||
| Maleb | 135 (90) | 44 (88) | 46 (92) | 45 (90) |
| Female | 15 (10) | 6 (12) | 4 (8) | 5 (10) |
| Median (IQR) age (yr) | 33.5 (27.0–40.0) | 35.0 (28.0–40.0) | 33.0 (27.0–41.0) | 33.5 (27.0–41.0) |
| Median (IQR) wt (kg) | 55.5 (52.0–59.3) | 55.0 (51.0–59.3) | 55.0 (52.0–59.3) | 56.0 (53.0–60.0) |
| No. (%) of subjects who were outpatients | 43 (29) | 13 (26) | 16 (32) | 14 (28) |
| No. (%) of HIV-positive subjects | 15 (10) | 4 (12) | 5 (10) | 6 (12) |
| No. (%) of subjects with the following MGIT resultc: | ||||
| Positive | 143 (95) | 48 (96) | 48 (96) | 47 (94) |
| Contaminated | 1 (1) | 0 | 0 | 1 (2) |
| Missing | 6 (4) | 2 (4) | 2 (4) | 2 (4) |
| No. (%) of subjects with the following result on LJc: | ||||
| Negative | 12 (8) | 3 (6) | 6 (12) | 3 (6) |
| 1+ | 40 (27) | 17 (34) | 12 (24) | 11 (22) |
| 2+ | 49 (33) | 12 (24) | 16 (32) | 21 (42) |
| 3+ | 9 (6) | 4 (8) | 3 (6) | 2 (4) |
| 4+ | 21 (14) | 6 (12) | 8 (16) | 7 (14) |
| Missing | 19 (13) | 8 (16) | 5 (10) | 6 (12) |
| No. (%) of subjects with the following ZN staining resultc: | ||||
| Negative | 0 | 0 | 0 | 0 |
| 1+ | 15 (10) | 4 (8) | 6 (12) | 5 (10) |
| 2+ | 51 (34) | 18 (36) | 18 (36) | 15 (30) |
| 3+ | 55 (37) | 18 (36) | 18 (36) | 19 (38) |
| 4+ | 24 (16) | 7 (14) | 7 (14) | 10 (20) |
| Missing | 5 (3) | 3 (6) | 1 (2) | 1 (2) |
| Median (IQR) TTP for MGIT (days)c | 5.13 (3.96, 6.71) | 5.10 (4.13, 6.58) | 4.92 (3.83, 6.71) | 5.13 (3.71, 6.79) |
| Median (IQR) no. of log CFUc | 5.25 (4.04, 6.79) | 5.25 (4.21, 6.79) | 5.29 (4.04, 6.75) | 5.13 (3.71, 6.79) |
a
HIV, human immunodeficiency virus; IQR, interquartile range; LJ, Lowenstein-Jensen medium; MGIT, mycobacterial growth indicator tube; TTP, time to positivity; ZN, Ziehl-Neelsen.
b
In Tanzania, there are generally more male than females admitted for the treatment of tuberculosis because of a benefit in access to health care. In previous studies in Tanzania, we observed that men were less likely to be under community-based directly observed treatment (DOT) (3) and relatively more men were hospitalized (4).
c
The result for the earliest positive culture within 14 days of randomization.